Biomedical Engineering

R&D collaboration with U of South Australia to focus on biopharmaceuticals

Published in Cancer Weekly, July 26th, 2005

Global nanotechnology company pSivida Limited (PSDV,) announced it has entered into a research and development collaboration with the Ian Wark Research Institute (the Wark) at the University of South Australia to evaluate the potential of its biosilicon platform for the delivery of protein- and peptide-based therapeutics.

Protein- and peptide-based drugs (or biopharmaceuticals), including antibodies, hormones and growth factors, already account for a substantial and increasing segment of the pharmaceutical market.

Biopharmaceuticals are used to treat a broad spectrum of conditions, ranging from cancer to diabetes and from anemia to osteoporosis....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-07-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry